Caraco Pharmaceutical Laboratories, Ltd. has been granted USFDA final approval of its Abbreviated New Drug Application (ANDA) for Glipizide tablets.
Glipizide tablets are the generic equivalent of Pfizer's Glucotrol®, an anti-diabetic drug indicated as an adjunct to diet for the control of hyperglycemia and the associated symptomatology in patients with non-insulin-dependent diabetes mellitus, (NIDDM) and Type-2 diabetes.
Caraco Pharmaceutical Laboratories, Ltd. Is a Detroit-based company that develops, manufactures and distributes generic and private-label prescription pharmaceuticals to the nation's wholesalers, distributors, drugstore chains and managed care providers.
With the USFDA approval, Caraco Pharma will manufacture and market both 5mg and 10mg Glizipide tablets.
Read more at Caraco Pharma.
.jpg)
Comment Preview